… Overcoming imatinib resistance with new compounds targeting essential signaling
pathways independent of BCR-ABL may provide an alternative therapeutic strategy. Plant-derived …

… Among them, the second-generation tyrosine kinase inhibitor dasatinib (DAS), … BCR-ABL/GUS
IS was also evaluated at diagnosis, as previously reported, and high levels of BCR-ABL/…

… inhibitors targeting the oncogenic kinase BCR-ABL constitutes a promising paradigm for
treating chronic myeloid … ) as a potent pan-BCR-ABL inhibitor against imatinib-resistant mutants, …

… Dasatinib inhibits multiple imatinib- resistant BCR::ABL1 mutant … the option of early change
to secondgeneration TKIs. At MDACC, a … Multiple BCR- ABL kinase domain mutations confer …

… After a median of 15 months, 10% of patients experienced disease progression, with 93%
of them having developed imatinib resistant disease [6]. The CA180-034 trial investigated …

… or Bcr-Abl. Overall, these results confirmed the conclusion that many imatinib-resistant Bcr-Abl
… successful to that approved by other secondgeneration TKIs E test 536 newly diagnosed …

… ) with tyrosine kinase inhibitors (TKIs) has … second-generation TKIs. The START A trial
enrolled 174 patients with CML-AP (imatinib resistant = 161, imatinib intolerant = 13), and treated …

… has made it an effective treatment for chronic myelogenous leukemia (CML)… Both BCR-Abl–independent
and BCR-Abl–dependent … -approved second- and third-generation inhibitors are …

… inhibits proliferation and induces apoptosis in bcr-abl positive cell lines as well as fresh
leukemic cells from Philadelphia chromosome positive chronic myeloid … ) or if Imatinib-resistant …

… to their current tyrosine kinase inhibitor (TKI) regime and … were developed to alleviate
imatinib resistant or intolerant CML … of the BCR-ABL fusion transcript followed by a second PCR …